Jennifer L Moran1, Kazuma Nakagawa2, Susan M Asai1, Matthew A Koenig3. 1. The Queen's Medical Center, Neuroscience Institute, Honolulu, Hawaii. 2. The Queen's Medical Center, Neuroscience Institute, Honolulu, Hawaii; Department of Medicine, The University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii. 3. The Queen's Medical Center, Neuroscience Institute, Honolulu, Hawaii; Department of Medicine, The University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii. Electronic address: mkoenig@queens.org.
Abstract
BACKGROUND: Stroke centers with limited on-site neurovascular physician coverage may experience delays in acute stroke treatment. We sought to assess the impact of providing 24/7 neurocritical care acute care nurse practitioner (ACNP) "stroke code" first responder coverage on treatment delays in acute stroke patients who received tissue plasminogen activator (tPA). METHODS: Consecutive acute ischemic stroke patients treated with intravenous tPA at a primary stroke center on Oahu between 2009 and 2014were retrospectively studied. 24/7 ACNP stroke code coverage (intervention) was introduced on July 1, 2011. The tPA utilization, door-to-needle (DTN) time, imaging-to-needle (ITN) time, and independent ambulation at hospital discharge were compared between the preintervention period (24 months) and the postintervention period (33 months). RESULTS: We studied 166 stroke code patients who were treated with intravenous tPA, 44 of whom were treated during the preintervention period and 122 of whom were treated during the postintervention period. After the intervention, the median DTN time was reduced from 53 minutes (interquartile range [IQR] 45-73) to 45 minutes (IQR 35-58) (P = .001), and the median ITN time was reduced from 36 minutes (IQR 28-64) to 21 minutes (IQR 16-31) (P < .0001). Compliance with the 60-minute target DTN improved from 61.4% (27 of 44 patients) in the preintervention period to 81.2% (99 of 122 patients) in the postintervention period (P = .004). The tPA treatment rates were similar between the preintervention and postintervention periods (P = .60). CONCLUSIONS: Addition of 24/7 on-site neurocritical care ACNP first responder coverage for acute stroke code significantly reduced the DTN time among acute stroke patients treated with tPA.
BACKGROUND:Stroke centers with limited on-site neurovascular physician coverage may experience delays in acute stroke treatment. We sought to assess the impact of providing 24/7 neurocritical care acute care nurse practitioner (ACNP) "stroke code" first responder coverage on treatment delays in acute strokepatients who received tissue plasminogen activator (tPA). METHODS: Consecutive acute ischemic strokepatients treated with intravenous tPA at a primary stroke center on Oahu between 2009 and 2014were retrospectively studied. 24/7 ACNPstroke code coverage (intervention) was introduced on July 1, 2011. The tPA utilization, door-to-needle (DTN) time, imaging-to-needle (ITN) time, and independent ambulation at hospital discharge were compared between the preintervention period (24 months) and the postintervention period (33 months). RESULTS: We studied 166 stroke code patients who were treated with intravenous tPA, 44 of whom were treated during the preintervention period and 122 of whom were treated during the postintervention period. After the intervention, the median DTN time was reduced from 53 minutes (interquartile range [IQR] 45-73) to 45 minutes (IQR 35-58) (P = .001), and the median ITN time was reduced from 36 minutes (IQR 28-64) to 21 minutes (IQR 16-31) (P < .0001). Compliance with the 60-minute target DTN improved from 61.4% (27 of 44 patients) in the preintervention period to 81.2% (99 of 122 patients) in the postintervention period (P = .004). The tPA treatment rates were similar between the preintervention and postintervention periods (P = .60). CONCLUSIONS: Addition of 24/7 on-site neurocritical care ACNP first responder coverage for acute stroke code significantly reduced the DTN time among acute strokepatients treated with tPA.
Authors: Ilana M Ruff; Syed F Ali; Joshua N Goldstein; Michael Lev; William A Copen; Joyce McIntyre; Natalia S Rost; Lee H Schwamm Journal: Stroke Date: 2014-01-07 Impact factor: 7.914
Authors: Gregg C Fonarow; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Maria V Grau-Sepulveda; DaiWai M Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm Journal: Circulation Date: 2011-02-10 Impact factor: 29.690
Authors: Jonathan Emberson; Kennedy R Lees; Patrick Lyden; Lisa Blackwell; Gregory Albers; Erich Bluhmki; Thomas Brott; Geoff Cohen; Stephen Davis; Geoffrey Donnan; James Grotta; George Howard; Markku Kaste; Masatoshi Koga; Ruediger von Kummer; Maarten Lansberg; Richard I Lindley; Gordon Murray; Jean Marc Olivot; Mark Parsons; Barbara Tilley; Danilo Toni; Kazunori Toyoda; Nils Wahlgren; Joanna Wardlaw; William Whiteley; Gregory J del Zoppo; Colin Baigent; Peter Sandercock; Werner Hacke Journal: Lancet Date: 2014-08-05 Impact factor: 79.321
Authors: Lisa M Caputo; Judd Jensen; Michelle Whaley; Mark J Kozlowski; Christopher V Fanale; Jeffrey C Wagner; Alessandro Orlando; David Bar-Or Journal: Neurohospitalist Date: 2016-10-21
Authors: Ruth M Kleinpell; W Robert Grabenkort; April N Kapu; Roy Constantine; Corinna Sicoutris Journal: Crit Care Med Date: 2019-10 Impact factor: 7.598
Authors: Md Golam Hasnain; John R Attia; Shahinoor Akter; Tabassum Rahman; Alix Hall; Isobel J Hubbard; Christopher R Levi; Christine L Paul Journal: Implement Sci Date: 2020-11-04 Impact factor: 7.327